Immutep Ltd
ASX:IMM

Watchlist Manager
Immutep Ltd Logo
Immutep Ltd
ASX:IMM
Watchlist
Price: 0.335 AUD -1.47% Market Closed
Market Cap: 487.3m AUD
Have any thoughts about
Immutep Ltd?
Write Note

Operating Margin
Immutep Ltd

-42 137.6%
Current
-19 287%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-42 137.6%
=
Operating Profit
-50.4m
/
Revenue
119.6k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
AU
Immutep Ltd
ASX:IMM
491.1m AUD
-42 138%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
315.2B USD
28%
US
Amgen Inc
NASDAQ:AMGN
141.9B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
116.4B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.5B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
135.7B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-22%
Country AU
Market Cap 491.1m AUD
Operating Margin
-42 138%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 315.2B USD
Operating Margin
28%
Country US
Market Cap 141.9B USD
Operating Margin
19%
Country US
Market Cap 116.4B USD
Operating Margin
38%
Country US
Market Cap 104.5B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 135.7B AUD
Operating Margin
26%
Country US
Market Cap 78.7B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36B EUR
Operating Margin
-22%
No Stocks Found

Immutep Ltd
Glance View

Market Cap
491.1m AUD
Industry
Biotechnology

Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The firm has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.

IMM Intrinsic Value
0.728 AUD
Undervaluation 54%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-42 137.6%
=
Operating Profit
-50.4m
/
Revenue
119.6k
What is the Operating Margin of Immutep Ltd?

Based on Immutep Ltd's most recent financial statements, the company has Operating Margin of -42 137.6%.